Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT01683305
Other study ID # Silbiotech:2012-01
Secondary ID
Status Not yet recruiting
Phase N/A
First received September 7, 2012
Last updated September 10, 2012
Start date March 2013
Est. completion date November 2014

Study information

Verified date September 2012
Source Silbiotech
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

This will be a Phase I study. During the Phase I study, our goals are: 1) screen a number of cancer biomarkers in Nipple Aspirate Fluid (NAF) from women who have no mammographically detectable tumors, and those who have detectable tumors, 2) identify all the detectable markers and 3) establish that biomarkers detected in NAF could also be detected in the biopsied tumor tissue that was removed for diagnostic purpose in subjects who have detectable tumors.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 500
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Any female subject aged 18 years or older

Exclusion Criteria:

Study Design

Observational Model: Cohort


Related Conditions & MeSH terms


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Silbiotech
See also
  Status Clinical Trial Phase
Suspended NCT01562626 - Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors Phase 1/Phase 2
Completed NCT00435669 - A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664) Phase 1
Completed NCT00400023 - A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors Phase 1
Completed NCT00395434 - Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Phase 1
Completed NCT00372437 - A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine Phase 1/Phase 2
Completed NCT00375245 - Rapamycin With Grapefruit Juice for Advanced Malignancies Phase 1
Completed NCT00410696 - Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy Phase 2
Recruiting NCT00553033 - Laparoscopic Liver Resection N/A
Completed NCT00248404 - NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS) Phase 1/Phase 2
Completed NCT00222443 - Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy Phase 1
Completed NCT00207103 - MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT03251924 - A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05103969 - Cohort of Tumors With POLE/D1 Mutation
Completed NCT00446446 - PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer) Phase 2
Completed NCT02275910 - Phase 1 Study of E7090 in Subjects With Solid Tumor Phase 1
Terminated NCT02271516 - to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage Phase 1
Completed NCT01448759 - Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel N/A
Terminated NCT01081808 - Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors Phase 1
Completed NCT00389480 - Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies Phase 1
Completed NCT00398814 - Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers Phase 1